The proof-of-concept of such new therapeutic approach is currently being evaluated using non-pathogenic anti-AQP4 antibodies (aquaporumab) for the treatment of neuromyelitis optica characterized by the presence of autoantibodies against AQP4 [144,145]. This evidence concerns the gene AQP4 and neuromyelitis optica.